Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Neurology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to Neurology Articles

Saturday 25th March, 2006

 

Donepezil reverses some aspects of cognitive deterioration seen in severe Alzheimer's disease.

 
 

tellfrnd.gif (30x26 -- 1330 bytes)send to a friend
 
prntfrnd.gif (30x26 -- 1309 bytes)printer friendly version
 
 
 
 
  Related
 
  Alzheimer's disease - new drugs and research look hopeful  
   
 
     

The drug donepezil can reverse some aspects of cognitive and functional deterioration seen in patients with severe Alzheimer's disease, according to a randomised trial published online today (Wednesday March 22, 2006) by The Lancet.

About 20% of Alzheimer's patients have severe dementia. As their health deteriorates they become less able to communicate, less mobile, and increasingly reliant on nursing care. Donepezil is used to treat mild-to-moderate Alzheimer's disease but its effectiveness in severe dementia has not been assessed until now.

In their trial Bengt Winblad (Karolinska Institutet, Huddinge, Sweden) and colleagues recruited Alzheimer's patients over 50 years of age from 50 nursing homes in Sweden. They assigned 95 patients to donepezil and 99 to a placebo for 6 months. The investigators found that those on donepezil had improved cognition and ability to carry out daily activities when compared with those on placebo. More patients on the active drug had side effects than those in the placebo group but these were usually transient and mild to moderate in severity.

Professor Winblad states: "Donepezil slows, and can reverse some aspects of deterioration of cognition and function in individuals with severe Alzheimer's who live in nursing homes."

Source

The Lancet

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright © 2001-2012 DoctorsLounge®. All rights reserved.